5 Things We Liked about October

October was packed full of activity and developments on EU health policy, and here is our pick of the bunch looking back on the month.

1) Debating the challenges of the 'new reality' at EHFG

You may have seen our many #ehfg tweets, based on the debates and presentations that unfolded at the European Health Forum Gastein. The EHFG seems like ages ago now, but it did take place in October! The event saw a suite of both EU and national level stakeholders come together to reflect on today's 'new reality', that is, the impact the fiscal crisis has already had on health in Europe. Consensus built over the week on the need for Europe's Member States to start create more resilient and sustainable health systems, and the importance of increased dialogue between national health and finance ministries to achieve this.

2) WHO on the benefits of sustainable health systems

A key enable in bringing together Member States to discuss the very issue of sustainable health systems has been the World Health Organization (WHO). WHO hosted a European Ministerial Conference on Health Systems in Tallinn, Estonia this month, underlining the message that investing in health is an investment in economies and societies as a whole. How far WHO member states have come in transforming health systems since the 2008 Tallinn Charter, a commitment to strengthen health systems, was a timely topic for the conference.

See our Health = Wealth blog on this topic here.

3) Dementia: Perceptions and complex issues

October also marked a key milestone for Alzheimer Europe, with their 23rd Annual Conference of Alzheimer Europe taking place around the theme of "Living well in a dementia-friendly society". The event explored the complex issues of how the perception and image of dementia impacts the lives of people with the disease and their carers. At the conference, Lilly called for greater education around clinical trials, following the results of a global survey of public, patients and caregivers which revealed the ongoing misperceptions that persist regarding the clinical trials process.

Check out this series of related blogs running up to, during and following the event:

4) Clinical trials data transparency, continued

On the subject of clinical trials, which has been a focus of discussion not just in October but for much of 2013, the European Forum for Good Clinical Practice (EFGCP) multi-stakeholder roundtable took place. This event looked at the interests of patients and research, and we were pleased our colleague Sue Forda, VP Global Regulatory Affairs International, had the opportunity at the event to reaffirm our industry commitments and relay what Lilly is doing as a company on this important topic. Check out this blog reporting on the event.

5) Last but not least: EFP kicked off its 2014 EU Election campaign

Lilly welcomed it back on the 1st October, and we want to show our support again for the European Patients' Forum (EPF) 2014 EU Elections campaign "Patients + Participation = Our Vote for a Healthier Europe". The campaign underlines the importance of putting patients at the centre of EU healthcare policies - a value welcomed by many including Commissioner Borg and us here at this blog. Let's hope the impending MEP campaigns build on this important message.

Here's our blog on the campaign.

We too will be looking to launch our 2014 EU Election campaign soon - so watch this space #EU2014Lilly.